FDA has approved Zolgensma, Novartis gene therapy against spinal muscular atrophy type 1, with a price of $2,125 million per patient. The treatment is the most expensive in history but, according to the swiss Company, the lifesaving benefit justifies the price, although a change in payment and reimbursement methods, in a system without lump sum payment capabilities, wil be needed. FDA uses a clinical trial data for its decision, that shows all of 15 infants treated with the drug were alive and without respiratory assistance at two years old